General Information of the Compound
Compound ID
CP0104146
Compound Name
2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid
    Show/Hide
Synonyms
(S)-2-(6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid
1000413-72-8
3-Benzofuranacetic acid, 6-[[2',6'-diMethyl-4'-[3-(Methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]Methoxy]-2,3-dihydro-, (3S)-
CHEMBL1829174
Fasiglifam
GLP1W4JXAH
J-501277
TAK 875
TAK-875
TAK875
UNII-GLP1W4JXAH
[(3s)-6-({2',6'-Dimethyl-4'-[3-(Methylsulfonyl)propoxy]biphenyl-3-Yl}methoxy)-2,3-Dihydro-1-Benzofuran-3-Yl]acetic Acid
    Show/Hide
Structure
Formula
C29H32O7S
Molecular Weight
524.635
Canonical SMILES
Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1
    Show/Hide
InChI
InChI=1S/C29H32O7S/c1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21(14-22)17-35-24-8-9-26-23(15-28(30)31)18-36-27(26)16-24/h4,6-9,12-14,16,23H,5,10-11,15,17-18H2,1-3H3,(H,30,31)/t23-/m1/s1
    Show/Hide
InChIKey
BZCALJIHZVNMGJ-HSZRJFAPSA-N
CAS
1000413-72-8
Physicochemical Property
logP
5.31364
Rotatable Bonds
11
Heavy Atom Count
37
Polar Areas
99.13
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
6
Complexity
37

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 24857286
SID: 50088191
ChEMBL ID
CHEMBL1829174
DrugBank ID
DB12491
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT02793, Free fatty acid receptor 1
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000006 HEK293 Homo sapiens (Human)  9
1
EC50 = 0.35 nM
   TI
   LI
   LO
   TS
2
EC50 = 1.9 nM
   TI
   LI
   LO
   TS
3
EC50 = 9.333 nM
   TI
   LI
   LO
   TS
4
EC50 = 12 nM
   TI
   LI
   LO
   TS
5
EC50 = 31 nM
   TI
   LI
   LO
   TS
6
EC50 = 39 nM
   TI
   LI
   LO
   TS
7
EC50 = 80 nM
   TI
   LI
   LO
   TS
8
EC50 = 160 nM
   TI
   LI
   LO
   TS
9
EC50 = 5100 nM
   TI
   LI
   LO
   TS
CL000011 CHO Cricetulus griseus (Chinese hamster)  13
1
EC50 = 14 nM
   TI
   LI
   LO
   TS
2
EC50 = 16 nM
   TI
   LI
   LO
   TS
3
EC50 = 27 nM
   TI
   LI
   LO
   TS
4
EC50 = 27.5 nM
   TI
   LI
   LO
   TS
5
EC50 = 29.6 nM
   TI
   LI
   LO
   TS
6
EC50 = 31.8 nM
   TI
   LI
   LO
   TS
7
EC50 = 32.5 nM
   TI
   LI
   LO
   TS
8
EC50 = 33.6 nM
   TI
   LI
   LO
   TS
9
EC50 = 37.1 nM
   TI
   LI
   LO
   TS
10
EC50 = 38.6 nM
   TI
   LI
   LO
   TS
11
EC50 = 45 nM
   TI
   LI
   LO
   TS
12
EC50 > 1000 nM
   TI
   LI
   LO
   TS
13
Kd = 11.9 nM
   TI
   LI
   LO
   TS
CL000094 1321N1 Homo sapiens (Human)  2
1
EC50 = 14.13 nM
   TI
   LI
   LO
   TS
2
EC50 = 57.54 nM
   TI
   LI
   LO
   TS
CL000460 Flp-In-T-REx-293 Homo sapiens (Human)  1
1
Ki = 28.84 nM
   TI
   LI
   LO
   TS
Biochemical Assays
1 EC50 = 53 nM
Protein ID: PT04613, Free fatty acid receptor 1
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000043 U2OS Homo sapiens (Human)  1
1
EC50 = 8.6 nM
   TI
   LI
   LO
   TS
Protein ID: PT02522, Free fatty acid receptor 1
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000043 U2OS Homo sapiens (Human)  1
1
EC50 = 36 nM
   TI
   LI
   LO
   TS
CL000006 HEK293 Homo sapiens (Human)  1
1
EC50 = 39 nM
   TI
   LI
   LO
   TS
Protein ID: PT04427, Free fatty acid receptor 4
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000011 CHO Cricetulus griseus (Chinese hamster)  1
1
EC50 > 10000 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( TAK-875 )
Drug Name TAK-875
Company Takeda Pharmaceuticals U.S.A.
Indication
Type-2 diabetes
Phase 3
Target(s)
Free fatty acid receptor 1 (GPR40)
Modulator